Blockbuster Oncology Brands Market 2030: Pharmacy Giants Dominate
Blockbuster Oncology Brands Market Growth & Trends The global blockbuster oncology brands market size is anticipated to reach USD 69.56 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 8.0% from 2024 to 2030. Shift towards immunotherapies coupled with an increasing number of indication expansion trials is one of the primary growth stimulants for the market. Current market analysis reveals Revlimid and Opdivo as bestselling therapies in the marketplace in 2017. However, a robust pipeline will uplift Opdivo’s sales, while Revlimid’s patent expiration will lower its revenue share in the market by 2027. Although Keytruda poses strong competition to Opdivo, especially after bagging a frontline approval for NSCLC in 2017, the immunotherapeutic is expected to trail behind the latter by 2027. Lifecycle management strategies, including the expansion of approved indications and development of c...